首页> 外文OA文献 >Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin'S Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT)

【2h】

Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin'S Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT)

机译：吉西他滨，白消安和美法仑（Gem / Bu / Mel）是一种新型的高剂量化学疗法（HDC）方案，在接受自体干细胞移植（ASCT）的难治性或低危复发非霍奇金淋巴瘤（NHL）患者中具有高活性）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Nieto Y.; Jones R.B.; Popat U.; Andersson B.; Valdez B.; Thall P.; Shpall E.J.; Chancoco C.; Alousi A.; Anderlini P.; Hosing C.; Qazilbash M.; Bashir Q.; Kebriaei P.; Khoui I.; Ciurea S.; Parmar S.; Rondon G.; Champlin R.;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma (T-NHL) Receiving an Autologous Stem Cell Transplantation (ASCT) [J] . Nieto Yago, Bassett Roland, Hosing Chitra, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2016,第3Suppla1期

机译：高剂量吉西他滨，白消安和美法仑（GEM / BU / MEL）和BEAM在接受自体干细胞移植（ASCT）的成熟T细胞非霍奇金淋巴瘤（T-NHL）并发患者队列中的比较
2. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma [J] . Yago Nieto, Peter F. Thall, Junsheng Ma, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第8期

机译：None
3. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies [J] . NietoY., ThallP., ValdezB., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2012,第11期

机译：大剂量吉西他滨联合白消安和美法仑联合自体干细胞移植治疗难治性淋巴恶性肿瘤
4. HIGH-DOSE MELPHALAN CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN 65 PATIENTS WITH AL AMYLOIDOSIS: ORGAN PROGRESSION CAN BE DELAYED IN PATIENTS REACHING COMPLETE REMISSION [C] . SO Schonland, J.B Dengler, M Hundemer, International Symposium on Amyloidosis . 2008

机译：在65例Al淀粉样蛋白患者中，具有自体蛋白化疗的高剂量蛋白化疗：器官进展可以延迟达到完全缓解的患者
5. Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan [O] . Yago Nieto, Benigno C Valdez, Sai R Pingali, -1

机译：大剂量吉西他滨/环丁砜/美法仑用于复发/难治性骨髓瘤自体干细胞移植的2期临床试验：与美法仑的配对配对比较
6. Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma (T-NHL) Receiving an Autologous Stem Cell Transplantation (ASCT) [O] . Yago Nieto, Roland Bassett, Chitra Hosing, 2016

机译：高剂量吉西他滨，伯林和梅酚（宝石/梅兰（Gem / Bu / Mel）和梁在同时患者群中的成熟T细胞非霍奇金淋巴瘤（T-NHL）接受自体干细胞移植（ASCT）

Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin'S Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT)

著录项

相似文献

相关主题

期刊订阅